XNAS · Healthcare · Biotechnology
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | Q3 2025 | — | -1.81 | — | $0 | — | — | — | — |
| 2025-08-12 | Q2 2025 | — | -0.45 | — | $0 | — | -5.02% | -31.39% | -36.12% |
| 2025-03-24 | Q4 2024 |
| — |
| -0.66 |
| — |
| $0 |
| — |
| -1.13% |
| -21.53% |
| -25.17% |
| 2024-11-14 | Q3 2024 | -2.40 | -0.76 | +68.33% | $0 | ✅ Beat | -2.90% | +5.80% | +0.46% |
| 2024-08-09 | Q2 2024 | -53.60 | -2.37 | +95.58% | $0 | ✅ Beat | -5.22% | -17.39% | -34.35% |
| 2024-05-13 | Q1 2024 | -53.60 | -3.28 | +93.88% | $0 | ✅ Beat | -7.12% | +2.00% | -8.53% |
| 2024-03-22 | Q4 2023 | -8.08 | -1.76 | +78.22% | $0 | ✅ Beat | — | — | — |
| 2023-08-10 | Q2 2023 | -10.40 | -11.44 | -10.00% | $0 | ❌ Miss | -5.92% | +27.63% | +21.97% |
Showing last 8 quarters.